BenevolentAI SPAC Presentation Deck

REAKOUT Benevolent Investment Highlights 1 Scientifically and technologically differentiated approach that has produced a rich portfolio of drug programmes. 3 5 6 Proven Al computational R&D engine scales identification and development of novel therapeutic candidates with higher probability of success Versatile platform is disease and drug modality agnostic, supported by deep experimental capabilities and optimised for patient-specific molecular mechanisms High-value partnerships with AstraZeneca and Eli Lilly validate scientific leadership and success of technology platform Highly credible and experienced team with unique ability to combine traditional research practices with Al technology at all stages of drug discovery, clinical trials and commercialisation Flexible business model with optionality to out-license drug candidates at different stages of clinical development. Numerous near-term value inflection proof points: Ulcerative Colitis candidate selected in Sep 2021 and Phase I/II readout for Atopic Dermatitis in mid 2022 Benevolent 40

View entire presentation